QR Pharma Release: Posiphen Restores Brain Function, Cognition and Memory in Transgenic Alzheimer Mice
10/22/2012 9:42:17 AM
More...
|
QR Pharma Announces the Start of a Phase I Clinical Study for Bisnorcymserine
7/24/2012 9:59:52 AM
More...
|
QR Pharma Awarded Funding by The Michael J. Fox Foundation to Test Posiphen® as a Treatment for Parkinson’s Disease
3/6/2012 8:43:16 AM
More...
|
QR Pharma Reports Results from SBIR Grant by NIA/National Institutes of Health (NIH) to Study Posiphen(R) and Metabolites in Various Models
10/13/2011 10:07:10 AM
More...
|
Jeffrey Cummings, Rachelle Doody, Martin Farlow and Mary Sano to Form QR Pharma’s Medical Advisory Board
2/3/2011 11:15:23 AM
More...
|
QR Pharma to Present at the 44th Winter Conference on Brain Research
1/19/2011 9:10:48 AM
More...
|
QR Pharma Receives FDA Clearance to Conduct Clinical Trials with Its Second Novel Alzheimer Compound, Bisnorcymserine
12/2/2010 10:41:12 AM
More...
|
QR Pharma Awarded SBIR Grant by National Institute on Aging/National Institutes of Health (NIH) to Test Posiphen(R) and Metabolites in Various Models
9/21/2010 10:06:15 AM
More...
|
Beacon Enterprise Solutions Announces Additional Contract with Fortune 100 Pharmaceutical Company
7/14/2010 11:01:09 AM
More...
|
QR Pharma’s Posiphen Was Shown in a Clinical Mechanism of Action Study to Enter the Brain and to Inhibit Amyloid Precursor Protein
7/14/2010 10:27:32 AM
More...
|
|